CA-125 is a large transmembrane protein that ovarian and other cancer cells shed. Robert Bast, M.D., discovered the protein in the early 1980s. Bast called the protein "cancer antigen 125" because it was recognized by the 125th monoclonal antibody produced against an ovarian cancer cell line. Today, it's used mainly to monitor the effects of chemotherapy.
In 1998, an e-mail beseeching women to undergo annual CA-125 screening for ovarian cancer spread across the Internet. "Please, please, p-l-e-a-s-e tell all your female friends and relatives to insist on a CA-125 blood test every year as part of their annual physical exams," pleaded the note from a cancer patient. "Don't take no for an answer."
Unfortunately, the science behind CA-125 screening wasn't ready for prime time then, and it still isn't. In June, a National Cancer Institute–sponsored randomized study published its long-awaited results in the Journal of the American Medical Association. The findings showed that simultaneous CA-125 and vaginal ultrasound screening did not affect ovarian cancer mortality. But this study used what some scientists say is an outmoded approach for tumor detection. Meanwhile, a different study is using a different screening approach that could be more promising. Thus CA-125 screening, which some still see as perhaps the best hope for early ovarian cancer detection, remains in limbo.CA-125 levels can rise in response to some benign conditions, including endometriosis, other ovarian diseases, and pregnancy. So, not only did the NCI study's screening approach not reduce mortality in ovarian cancer, it also led to many surgeries performed to investigate positive screening results. Of 3,285 women with false-positive results, 1,080 underwent surgical follow-up, and among them, 163 women—15% in all—experienced at least one serious complication.
The most diagnostically powerful panel consists of 23 biomarkers, including CA-125. Some of these markers will one day reside on a nanochip, which can deliver predictive estimates from a simple blood sample in a matter of minutes. As for using CA-125 to assess treatment benefits now, the rate of CA-125 decline does not predict the likelihood of achieving a long-term response to therapy. But this finding doesn't negate that CA-125 is an effective predictor of relapse and treatment response. In women previously treated for ovarian cancer and who have no current evidence of disease, a rising CA-125 [level] is a very sensitive predictor of relapse. CA-125 is also good measure of response to therapy—if CA-125 falls, the tumor is responding.
No comments:
Post a Comment